NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis → The AI Stock that’s Disrupting Every Industry (From StockEarnings) (Ad) Free HSGX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.32▼$1.4150-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume5.00 million shsAverage Volume9.06 million shsMarket Capitalization$124.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Histogenics alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Histogenics Stock (NASDAQ:HSGX)Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. HSGX Stock News HeadlinesApril 8, 2023 | thetimes.co.ukFeargal Sharkey: Desperate revival of failed policies doesn’t add upSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - StreetInsider.comMay 3, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...September 21, 2022 | businesswire.comAspect Biosystems Appoints Three New Board Members - Business WireAugust 24, 2022 | investing.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 5, 2022 | stockhouse.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseJune 23, 2022 | gurufocus.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comMay 25, 2022 | uk.investing.comOcugen Diversifies Its Pipeline With New Cell Therapy Platform By Benzinga - Investing.com UKMay 3, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...May 25, 2022 | globenewswire.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GlobeNewswireMay 24, 2022 | streetinsider.comOcugen (OCGN) Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - StreetInsider.comApril 18, 2022 | streetinsider.comForm DEF 14A Aurinia Pharmaceuticals For: Apr 18 - StreetInsider.comMarch 8, 2022 | investorplace.comOcugen Is Two Strikes in With a Third in the Books - InvestorPlaceOctober 26, 2021 | news.yahoo.comCN.ORTH: New Blood on The Board - Yahoo FinanceSeptember 21, 2021 | prnewswire.comGlobal Cell Therapy Market Outlook, Patent & Clinical Trials Report 2021-2028: Clinical & Commercial Insight On 32 Cell Therapies Available & Insight on 1600+ Cell Therapies in Clinical Trials - PRNewswireSeptember 8, 2021 | streetinsider.comForm 8-K APPLIED GENETIC TECHNOLO For: Sep 08 - StreetInsider.comSee More Headlines Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CUSIPN/A CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-132.00Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$124.87 million OptionableNot Optionable Beta3.10 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Adam D. Gridley (Age 47)Interim Pres, CEO Treasurer, Sec., Consultant & Director Mr. Jonathan I. Lieber (Age 49)Interim Chief Financial Officer Mr. Stephen R. Kennedy (Age 62)Consultant Key CompetitorsInogenNASDAQ:INGNEnvoy MedicalNASDAQ:COCHCollPlant BiotechnologiesNASDAQ:CLGNVicarious SurgicalNYSE:RBOTMilestone ScientificNYSE:MLSSView All Competitors HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Biosciences (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Trevena (TRVN), OPKO Health (OPK) and Synergy Pharmaceuticals (SGYP). When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:HSGX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBill Gates is all about this tiny $2 stockTimothy SykesTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
